Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Clinical Care/Education/Nutrition

The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients

  1. Sandeep Dhindsa, MD1,
  2. Vishal Bhatia, MD2,
  3. Gurkiran Dhindsa, MBBS1,
  4. Ajay Chaudhuri, MD2,
  5. Gopalakrishna Murthi Gollapudi, MD, PHD1 and
  6. Paresh Dandona, MBBS, DPHIL2
  1. 1Diabetes Center of the Southwest, Midland, Texas
  2. 2Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, Buffalo, New York
  1. Address correspondence and reprint requests to Sandeep Dhindsa, MD, Diabetes Center of the Southwest, 10 Desta Dr., Suite 190, Midland, TX 79707. E-mail: sandhindsa{at}yahoo.com
Diabetes Care 2007 Jul; 30(7): 1860-1861. https://doi.org/10.2337/dc07-0337
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • BMC, bone mineral content
  • BMD, bone mineral density
  • DEXA, dual-energy X-ray absorptiometry

It is known that type 2 diabetes is frequently associated with hypogonadism in male subjects (1,2). Free testosterone concentrations are negatively related with BMI in type 2 diabetic patients (1,3). However, the relationship of free testosterone with adipose tissue mass and lean body mass in diabetic patients is not well described. Studies examining this relationship have been limited by the fact that they have not measured free testosterone by a reliable method such as equilibrium dialysis (4).

Therefore, we decided to study the body composition of hypogonadal and eugonadal type 2 diabetic patients by using dual-energy X-ray absorptiometry (DEXA) to measure subcutaneous adipose tissue, lean body mass, bone mineral content (BMC), and bone mineral density (BMD).

RESEARCH DESIGN AND METHODS—

The study was conducted in two endocrinology practices in Midland, Texas, and Buffalo, New York. It is our practice to screen all diabetic patients for hypogonadism, due to the high prevalence of hypogonadism in diabetic patients. We also routinely evaluate body composition of our diabetic patients by DEXA (done at no cost to our patients). Therefore, informed consent was not obtained.

Data from 164 consecutive male diabetic patients who presented to the endocrinology clinic were prospectively collected for the study. Patients with known history of hypogonadism; panhypopituitarism; a chronic debilitating disease such as renal failure, cirrhosis, HIV, back or hip surgery; or treatment with steroids, bisphosphonates, or recombinant parathyroid hormone were excluded. A total of 26 patients were disqualified, based on the study criteria. Therefore, data on 138 patients were included for analysis in this study. Fasting blood samples were then obtained to measure serum total testosterone, free testosterone, sex hormone–binding globulin, and A1C, using assays previously described (1). Free testosterone was measured by equilibrium dialysis (Esoterix laboratories) (normal range 0.174–0.868 nmol/l).

We measured total body mass, lean mass, subcutaneous fat mass, BMC, and BMD by DEXA (Lunar machine; General Electric Medical Systems). Measurements were made in both arms and legs and the trunk region. BMD was measured at both arms and legs, ribs, L1–L4 spine, and both hips. Hip BMD was defined as the mean BMD of both hips. Data are presented as means ± SE.

RESULTS—

Data from 138 male type 2 diabetic subjects were analyzed. The mean age of the patients was 59.29 ± 0.97 years (range 29.8–84.3). The mean BMI was 31.83 ± 0.44 kg/m2 (18.4–44.6). The mean total testosterone, free testosterone, and sex hormone–binding globulin concentrations were 13.29 ± 0.49 nmol/l (5.17−35.97), 0.184 ± 0.007 nmol/l (0.073–0.465), and 56.72 ± 2.45 nmol/l (8.5–156.0), respectively. Free testosterone was inversely related to BMI (r = −0.19, P = 0.04) and to arm (r = −0.18, P = 0.05), leg (r = −0.24, P = 0.03), trunk (r = −0.20, P = 0.04), and total (r = −0.23, P = 0.02) subcutaneous fat mass. Total testosterone was also inversely related to arm, leg, trunk, and total (r = −0.38, −0.38, −0.40, and −0.41, respectively; P < 0.001) fat mass. Free testosterone and total testosterone were positively related to arm lean mass (r = 0.36, P < 0.001 and r = 0.19, P = 0.05) but not to leg or total lean mass. Free testosterone and total testosterone were positively related to arm BMC (r = 0.27 and 0.31, respectively; P < 0.01) but not to leg or total BMC. Free testosterone was positively related with BMD in arms (r = 0.20, P = 0.04) and ribs (r = 0.28, P < 0.01). Total testosterone was positively related to rib (r = 0.18, P = 0.05) but not arm (r = 0.11, P = 0.25) BMD. Free testosterone and total testosterone were not related to leg, hip, spine, or total BMD.

Total BMD was positively related to total lean mass (r = 0.50, P < 0.01), total fat mass (r = 0.34, P < 0.01), and BMI (r = 0.37, P < 0.01). In a multiple regression model with total BMD as the dependent variable, and BMI, total lean mass, and total fat mass as independent variables, only total lean mass was a significant predictor of total BMD. Body composition of hypogonadal (n = 66) with eugonadal (n = 72) patients is presented in Table 1.

CONCLUSIONS—

Our study demonstrates a strong inverse relation among total testosterone, free testosterone, and subcutaneous fat mass in type 2 diabetic patients. Because hypogonadal type 2 diabetic subjects have higher subcutaneous fat mass, they may be more insulin resistant than eugonadal type 2 diabetic subjects. Therefore, it is relevant that type 2 diabetic patients with hypogonadism have markedly elevated C-reactive protein concentrations; thus, this may pose a marked increase in cardiovascular risk (5). The relationship of obesity with testosterone is probably bidirectional (6,7), with hypogonadism possibly being both the cause and consequence of increased adiposity. From our study, it is not possible to determine whether increased subcutaneous fat mass is the cause or consequence of hypogonadism.

Free testosterone was related positively to arm lean mass but not to leg or total lean mass. It is known that diabetic subjects have higher muscle mass (due to higher BMI) but poorer muscle strength (8). We did not measure muscle strength in our study. Because testosterone has a positive effect on muscle strength, it is possible that hypogonadal diabetic patients have poorer muscle strength than eugonadal diabetic patients, despite having a similar lean body mass.

Free testosterone was positively related to BMD in arms and ribs but not at other sites. It is possible that hypogonadism may have affected BMD at various sites differently, causing a more pronounced or rapid bone loss (or slower bone replacement) at arms and ribs compared with legs, hips, or the spine. Hypogonadism has previously been known to be associated with low BMD at the hip and spine (10). However, studies have not specifically been done in obese subjects. From our study, it appears that hypogonadism in obese type 2 diabetic subjects is not a major risk factor for developing osteopenia in the hips or spine. We do not know if this would be true if a more elderly diabetic population or a larger number of patients was studied. It would be important to determine whether replacement therapy with testosterone in hypogonadal diabetic males will reverse adiposity, improve BMD in the arm and ribs, and improve cardiovascular outcomes.

View this table:
  • View inline
  • View popup
Table 1—

Comparison of body composition of hypogonadal and eugonadal patients

Acknowledgments

We are thankful to Christie Hinton, bone density technician, and physician assistants Harold Hall and Marie Hall for their assistance during the study.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 6 April 2007. DOI: 10.2337/dc07-0337.

    S.D. has received lecturing fees from Solvay, Novartis, and Auxilium.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted March 27, 2007.
    • Received February 17, 2007.
  • DIABETES CARE

References

  1. ↵
    Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P: Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462–5468, 2004
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60:762–769, 2006
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R, Dandona P: Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 29:1120–1122, 2006
    OpenUrlFREE Full Text
  4. ↵
    Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM: Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 87:4522–4527, 2002
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P: Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29:2289–2294, 2006
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ: Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636–2641, 2005
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28:1636–1642, 2005
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB: Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 55:1813–1818, 2006
    OpenUrlAbstract/FREE Full Text
  9. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1–7, 1996
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Orwoll ES, Klein RF: Osteoporosis in men. Endocr Rev 16:87–116, 1995
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 30 (7)

In this Issue

July 2007, 30(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients
Sandeep Dhindsa, Vishal Bhatia, Gurkiran Dhindsa, Ajay Chaudhuri, Gopalakrishna Murthi Gollapudi, Paresh Dandona
Diabetes Care Jul 2007, 30 (7) 1860-1861; DOI: 10.2337/dc07-0337

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients
Sandeep Dhindsa, Vishal Bhatia, Gurkiran Dhindsa, Ajay Chaudhuri, Gopalakrishna Murthi Gollapudi, Paresh Dandona
Diabetes Care Jul 2007, 30 (7) 1860-1861; DOI: 10.2337/dc07-0337
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS—
    • RESULTS—
    • CONCLUSIONS—
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
  • Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor
Show more Clinical Care/Education/Nutrition

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.